Suven Life Sciences Ltd Q3 FY20 Share Price & Earnings Call Analysis

41out of 100

Momentum score · price trend

41 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,874 stocks
Last 12 months+48.9%83%
Last 6 months+95.2%92%
Last 3 months+3.5%64%

The price is 21.4% below its all-time high of ₹392.05 (31 Aug 2026). Stocks more than 20% below their peak have their score halved, so 83 became 41.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,874 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Suven Life Sciences Ltd: 0.4 × 83 + 0.4 × 92 + 0.2 × 64 = 83, halved to 41 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 1 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Financials of Suven Life Sciences Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Suven Life Sciences Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +3432213212132
Expenses +343227493332554145538110652
Operating Profit-32-28-24-46-30-31-52-39-44-51-80-103-51
OPM %-1,208%-737%-768%-1,885%-1,267%-3,024%-2,032%-2,435%-2,981%-2,714%-8,671%-3,678%-3,331%
Other Income +66136444211437
Interest0000000000000
Depreciation2222211211112
Profit before tax-28-24-13-42-28-28-50-39-44-52-77-102-46
Tax %0%0%0%0%-4%0%0%0%0%0%0%0%0%
Net Profit +-28-24-13-42-27-28-50-39-44-52-77-102-46
EPS in Rs-1.27-1.10-0.58-1.91-1.22-1.29-2.28-1.79-2.01-2.36-3.40-4.48-1.73

Financials of Suven Life Sciences Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +521499543625286131312141277
Expenses +36139841442730012893134139140172292
Operating Profit159102129198-14-116-80-122-126-128-166-284
OPM %31%20%24%32%-5%-917%-593%-1,032%-929%-1,094%-2,487%-4,001%
Other Income +919212327148514291114
Interest566521110000
Depreciation12182121114447666
Profit before tax152981231960-106-77-122-118-106-161-276
Tax %28%26%29%37%15,038%-11%-7%0%0%-1%0%0%
Net Profit +1097287124-24-94-72-122-118-105-161-276
EPS in Rs5.703.764.576.48-1.25-4.94-3.78-5.59-5.42-4.82-7.37-10.48
Dividend Payout %7%35%15%15%-80%0%0%0%0%0%0%0%

Financials of Suven Life Sciences Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital131313131313131522222226
Reserves547583654755226131958235424888565
Borrowings +109837134365321017
Other Liabilities +1057478118623316912142516
Total Liabilities773751816919303182128108389285135624
Fixed Assets +1723053063082225213837286073
CWIP1077102500540004
Investments003012792230045467622181
Other Assets +494439199308581571032230518153367
Total Assets773751816919303182128108389285135624

Financials of Suven Life Sciences Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1436810970-53-135-96-128-116-115-154-302
Cash from Investing Activity +-110-39-311-13014656-22-24894155-462
Cash from Financing Activity +179-68-30-525335146396-1-1757
Net Cash Flow212-39-23217-1814-5-432-220-7
Free Cash Flow25107928-92-137-102-147-119-113-191-307
CFO/OP113%93%111%57%262%114%119%104%91%95%93%106%

Financials of Suven Life Sciences Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days28393136366484022407378
Inventory Days1651832223290
Days Payable897891134
Cash Conversion Cycle105144162231366484022407378
Working Capital Days49554282237041,084234265101-4409,156
ROCE %13%15%24%-4%-54%-58%-118%-53%-36%-87%-77%

Continue your research

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • KMC Speciality Hospitals (India) Ltd (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • KMC Speciality Hospitals (India) Ltd (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • Vimta Labs Ltd (Q3 FY25)

    Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • 3B Blackbio DX Ltd (Q4 FY24)

    41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Manipal Health